ArticleFrontiers in cardiovascular medicine2025
Exploring the molecular intersection for hypertension, hyperlipidemia and their comorbid conditions through multi-omics approaches.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertension and hyperlipidemia are interconnected conditions that heighten cardiovascular risk, yet their intricate multi-scale molecular signatures remain inadequately mapped. This study aimed to conduct an integrated multi-omics investigation to unravel the key pathways and biomarkers underlying hypertension, hyperlipidemia, and both conditions. Methods: Metabolomic analysis was performed on serum samples and metagenomic analysis on fecal samples collected from individuals with hypertension ( Results: Metabolomics uncovered altered levels of sphingolipids, phosphatidylcholines, glycylprolines, and nucleic acid metabolites, which may be associated with changes in vascular tone, lipid and protein homeostasis, and thyroid signaling. Metagenomics showed depletion in the abundance of the Fibrobacteres phylum. Altered abundances of Conclusions: This multi-omics landscape of comorbid disease pathways and biomarkers lays the foundation for precision diagnosis and treatment of prevalent cardiovascular conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.